Antineoplastics, also known as anticancer drugs or chemotherapeutic agents, are medications used to treat cancer by inhibiting the growth and proliferation of malignant cells. They work through various mechanisms, such as damaging DNA, interfering with cell division, or blocking specific molecular pathways involved in tumor growth. Common classes include alkylating agents, antimetabolites, anthracyclines, and targeted therapies. Understanding their mode of action is essential for effective cancer treatment planning.

Antineoplastic drugs often cause side effects due to their impact on both cancerous and healthy rapidly dividing cells. Common side effects include nausea, vomiting, hair loss, fatigue, bone marrow suppression (leading to anemia or increased infection risk), and mucositis. Some newer targeted antineoplastics may have milder side effect profiles but can still cause specific toxicities like skin rashes or cardiac issues. Managing these side effects is a critical part of oncology care.

In pharmaceutical manufacturing, antineoplastics are typically classified based on their chemical structure and mechanism of action. Major categories include alkylating agents (e.g., cyclophosphamide), antimetabolites (e.g., methotrexate), plant alkaloids (e.g., vincristine), antitumor antibiotics (e.g., doxorubicin), and newer targeted agents like tyrosine kinase inhibitors (e.g., imatinib). This classification helps manufacturers develop appropriate synthesis routes, quality controls, and safety protocols during production.

The production of antineoplastic active pharmaceutical ingredients (APIs) must comply with stringent international quality standards, including Good Manufacturing Practices (GMP) as defined by the FDA, EMA, and ICH guidelines. Due to their high potency and toxicity, additional containment and occupational safety measures—such as those outlined in ISPE’s Risk-Based Manufacture of Pharmaceutical Products (Risk-MaPP)—are often required. Rigorous testing for purity, identity, potency, and impurities is mandatory to ensure patient safety and therapeutic efficacy.

Reputable suppliers implement strict safety protocols for handling and transporting antineoplastic intermediates, which are often classified as hazardous or highly potent compounds. This includes using closed-system transfer devices, specialized containment facilities, and personnel protective equipment (PPE). For transport, materials are packaged according to IATA and UN regulations for dangerous goods, with clear labeling and documentation. Certificates of Analysis (CoA) and Safety Data Sheets (SDS) are provided to ensure regulatory compliance and end-user safety.